OncoHost

12/24/2025

As the year comes to a close, we celebrate the progress made together and the milestones achieved. Thank you for being an invaluable part of our journey.

Here’s to continuing our work together, turning challenges into opportunities, and advancing care for patients worldwide.

Wishing you and your loved ones a joyful holiday season and a healthy, prosperous New Year.

Warmest wishes from all of us at OncoHost! 🎄✨

#2026

12/22/2025

📄🧬PROphet is being recognized in the peer-reviewed biomarker landscape for metastatic NSCLC

A recently published review in Lung Cancer: Targets and Therapy (DovePress / Dove Medical Press) highlights blood-based proteomic predictors of immune checkpoint inhibitor (ICI) response - and specifically calls out PROphet as a multi-analyte platform with clinical planning value.

In the review, PROphet is benchmarked in the top-tier evidence bracket across modalities with a score of 14 - the highest among proteomic & genomic predictors of poor ICI response in NSCLC reviewed (table 5). Score 14 reflects the highest rating of consistency, statistical validity, relevant endpoint, confounder adjustment, external validation, large cohort, and data availability.

Notable excerpts from the review:

- “Multi-analyte platforms such as PROphet demonstrated promising risk-stratification potential.”
- “Blood-based proteomic platforms such as PROphet… have shown value alongside PD-L1 testing for treatment planning in metastatic NSCLC.”
- “A machine learning–based proteomic test termed PROphet… derived from 388 proteins, stratified patients into groups with differential benefit,” spanning immune regulatory and stromal pathways—reflecting systemic influences on immunotherapy efficacy.

This is the direction the field is moving: integrated decision support - using systemic biology to complement tumor-only markers, and helping clinicians plan with more confidence.

Read the full review here: https://www.dovepress.com/article/download/109957

12/16/2025

In a thoughtful CTech deep-dive on the real trajectory of in , our CEO, Dr. Ofer Sharon, shares a grounded perspective on where meaningful progress is actually happening and where expectations need recalibration.

As cancer increasingly affects younger populations, the conversation is shifting from speed and scale to precision, sustainability, and clinical responsibility. Ofer underscores a critical truth: AI in medicine doesn’t move at consumer-tech velocity - and it shouldn’t. Real impact comes from rigorously validated models, biologically explainable insights, and that can be integrated into everyday clinical decision-making.

Read the full article here: https://bit.ly/4pHlqlh

As AI hype accelerates, oncology’s real progress is happening quietly, driven by data, regulation, and the slow work of making cancer treatment more precise and sustainable

12/15/2025

Wishing our partners, colleagues, and the global healthcare community a joyful Hanukkah filled with light, hope, and meaningful moments.

12/11/2025

🚭 Myth vs. Reality: Unveiling Lung Cancer Misconceptions 🫁

At OncoHost, we’re committed to cutting through the noise and elevating the conversation around lung cancer - because informed decisions start with accurate information.

12/10/2025

👉 Did you know?
Resistance to in non-small cell lung cancer ( ) isn't random. It’s biological. And OncoHost is uncovering the why behind it.

Our PROphet® platform uses a set of 388 resistance-associated proteins (RAPs) to predict the clinical benefit to immune checkpoint inhibitors.

A recent study showed that these RAPs are linked to key hallmarks—like invasion, metastasis, and immune suppression—and may even serve as drug targets. This opens the door to more precise, personalized treatment strategies for patients who might otherwise face resistance.

RAP profiles help us understand outcomes - before treatment begins.

Your insights. Amplified. By PROphet®.

Learn more about RAPs here:

Background Immune checkpoint inhibitors (ICIs) have shown substantial benefit for patients with advanced non-small cell lung cancer (NSCLC). However, resistance to ICIs remains a major clinical challenge. Here, we perform a comprehensive bioinformatic analysis of plasma proteomic profiles to explore...

12/09/2025

📣 Thank you, Mobile Health Times, for spotlighting our latest achievement!

We’re honored to be featured in your coverage of OncoHost’s Gold win in the 2025 Merit Awards for Healthcare – Technology Solution of the Year.

Read the full piece here:
https://bit.ly/4puV5Xs

Awards and Recognition OncoHost Wins Gold in 2025 Merit Awards for Healthcare ByCharlie Thomas December 8, 2025December 8, 2025 PROphet® Platform Recognized as Technology Solution of the Year for Advancing Precision Oncology OncoHost, a biotechnology company focused on precision oncology through pr...

12/04/2025

🏆 Gold Winner!

We are excited to announce that OncoHost has been awarded 'Technology Solution of the Year' in the 2025 Merit Awards for Healthcare for our PROphet® precision-oncology platform.

AI + = a new era of predictive, personalized cancer care.

🔗 Learn more: https://prn.to/4q8sZBp

12/03/2025

PROphetNSCLC® provides insights to answer the question: Which first-line therapy is more likely to improve overall survival of the patient?

✔️ One blood draw
✔️ Results 8 days from sample receipt at our CLIA-certified and CAP-accredited lab
✔️ Guides first-line treatment decisions

Transform complex data into actionable guidance to deliver care that's truly individualized: https://bit.ly/432ksp4

12/01/2025

📣 New Study Links Tattoos to Higher Melanoma Risk

A new Swedish study reports that people with tattoos may have a 29% higher risk of developing melanoma. The research found no increased risk for squamous cell carcinoma, and results remained consistent even after accounting for UV exposure, skin type, and lifestyle factors.

While the study does not prove causation, it highlights the need for continued research into tattoo ink, chronic inflammation, and long-term health effects.

https://bit.ly/4pIkb4R

For now, the guidance remains unchanged:
☀️ Protect your skin from UV radiation
👀 Monitor for new or changing moles
🩺 Seek medical evaluation when in doubt

No increased risk was found for another UV-related skin cancer, squamous cell carcinoma.

11/28/2025

Odds are, someone you know will be diagnosed with in their lifetime.

It's not just a statistic—it's your friend, your colleague, your loved one. This disease doesn't discriminate.

It's time we all become advocates. Know the signs, support screening, and stand with those fighting.

11/27/2025

Happy to all! We are grateful for our dedicated team, supportive partners, and the patients who inspire our work every day. May your day be filled with hope, health, and gratitude.